Nightingale Health Secures €20 Million in Funding Led by EIB with GSK and Sanofi Participation to Advance Blood Analysis Platform for Chronic Disease Prediction

VCBeat (WeChat Official Account: vcbeat) has learned that Finnish biotechnology company Nightingale Health has completed a €20 million financing round, led by the EIB (European Investment Bank) led the investment, GSK Venture Fund (GSK Venture Fund) and Sanofi (Sanofi）Co-investment. This fund will be usedto further develop its blood analysis technology, facilitating better prediction and prevention of chronic diseases.

Pharmaceutical Giant GSK(GlaxoSmithKline)and Sanofi(Sanofi)Recently joined the FinnGen research project, a public-private partnership aimed at collecting and analyzing genomic and health data from 500,000 participants in Finland’s national health registries. The investment in Nightingale Health represents a significant strategic move by the two companies following their participation in the FinnGen research project.

Nightingale Health is headquartered in FinlandHelsinki'sBiotechnology companies, by experts in healthcare, IT, and businessStudyComposed of experts. Nightingale Health operates two franchised laboratories in the UK, regularly serving international academic researchers, healthcare professionals, and industrial clients. Nightingale Health aims to address the world’s leading health challenge—chronic diseases. Through its proprietary blood analysis platform, Nightingale Health enhances predictive capabilities for conditions such as cardiovascular disease and diabetes.

In June last year, Nightingale Health announced the analysis of biomarkers from 500,000 blood samples sourced from the UK Biobank. Leveraging its advanced metabolic profiling technology, which measures disease-indicative molecules in the blood, Nightingale Health can extract more than 220 biomarkers from a single blood sample. While this technology is currently being employed in public health research, Nightingale Health has stated that its long-term goal is to replace traditional biomarker testing for chronic diseases.

EIB Vice President Alexander Stubb stated, “The EIB is committed to supporting companies like Nightingale Health that can play a tangible role in improving the health of EU citizens.”

“The addition of new partners will accelerate the achievement of our goals, introduce a suite of new analytical methods, and further enhance the speed of sample collection for FinnGen,” said Aarno Palotie, Scientific Director of the FinnGen research project.

The FinnGen research project is an unprecedented global initiative aimed at improving human health through genetic research and ultimately identifying new diagnostic methods for treating a variety of diseases. Compared with many ongoing studies, the collaborative nature of this project is particularly prominent. FinnGen brings together Finnish universities, hospitals, biobanks, and international pharmaceutical companies, led byFinnish BusinessFunded by the company and international pharmaceutical companies, including AbbVie, AstraZeneca, Biogen, Celgene, Genentech, GSK, Merck & Co. (Kenilworth, NJ, USA), Pfizer, and Sanofi.

The European Investment Bank is a publicofInternational Financial Institutions, headquartered in Luxembourg, is the world's largest international public lending institution, with its shareholders beingEU Member States。

GSK Venture Fund is a science-led global healthcare company with the mission to help people do more, feel better, and live longer.

Sanofi is a healthcare company engaged in the research, development, manufacturing, and marketing of innovative therapeutic solutions. Sanofi’s portfolio spans diabetes solutions, human vaccines, innovative medicines, consumer healthcare, emerging markets, animal health, and new enzyme technologies. Its products include prescription and over-the-counter medications for thrombosis, cardiovascular diseases, diabetes, central nervous system disorders, oncology, general internal medicine, as well as vaccines and other medical products.